| HOME >> MEDICINE >> TECHNOLOGY |
"MEK inhibitors may have broad utility in the treatment of human cancers and inflammatory diseases. We are pleased to have two compounds in this class, both with excellent preclinical profiles and promising human pharmacokinetics, moving forward in clinical development," said Barry D. Quart, PharmD, Ardea Biosciences' President and CEO. "We constantly strive to diminish the inherent risk of drug development by having multiple compounds, from structurally different chemical classes, moving through development and we are excited to complete Phase 1 testing of our lead MEK inhibitor, RDEA119, and progress RDEA436 into Phase 1 clinical testing, in the second half of 2008."
The posters are available on the Company website (http://www.ardeabio.com/) under the titles "RDEA119, a Potent and Highly Specific MEK Inhibitor is Efficacious in Mouse Tumor Xenograft Studies" and "RDEA436, a Novel MEK Inhibitor with Favorable Pharmacokinetic Properties."
About RDEA119 and RDEA436
RDEA119 and RDEA436, non-ATP competitive, highly-selective MEK inhibitors for the treatment of cancer and inflammatory diseases, are two of the compounds from Ardea's MEK inhibitor research and development program. RDEA119 has shown potential as a potent and selective inhibitor of MEK, which is believed to play an important role in cancer cell proliferation, apoptosis and metastasis. Preclinical and clinical results suggest that RDEA119 has favorable properties, including oral dosing, excellent selectivity and limited retention in the brain, which, in turn, may result in a reduced risk of central nervous system (CNS) side effects. Preclinical data shows that RDEA436 is a potent in vitro and in vivo inhibitor of MEK, has favorable pharmacokinetic properties with low CNS penetration and a long half-life in a human micro-dose study indicating the potential for once daily dosing in humans.
About Ardea Biosciences
Ardea
'/>"/>
| SOURCE Ardea Biosciences, Inc. Copyright©2008 PR Newswire. All rights reserved |